microchip technology incorporated Jobs in Basel

11 microchip technology incorporated Stellenangebote in Schweiz. Täglich aktualisierte Angebote.


  • Basel, Basel City, Schweiz IQVIA Vollzeit

    Instrument Licensing Solutions and Patient Site Strategy helps organizations understand how patients feel and function in clinical research and routine care. The team develops and manages the instruments used to capture patient experience, oversees permissions and licensing, and guides the evolution and integration of patient- and site-facing technologies...


  • Basel, Basel-Stadt, Schweiz IQVIA Argentina Vollzeit

    pbInstrument Licensing Solutions and Patient Site Strategy /b helps organizations understand how patients feel and function in clinical research and routine care. The team develops and manages the instruments used to capture patient experience, oversees permissions and licensing, and guides the evolution and integration of patient- and site-facing...


  • Basel, Schweiz Revolution Medicines Vollzeit

    Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target...

  • Space Manager

    Vor 2 Wochen


    Basel, Basel-City, Schweiz Exyte GmbH Vollzeit

    Discover your exciting role We are seeking a Space Manager (m/f/d) to join our team in Basel. This role is integral to the design and construction phases of our complex facilities, particularly within the life sciences and advanced technology sectors. Explore your tasks and responsibilities • Coordinate design aspects across disciplines and cover...


  • Basel, Basel, BS, Schweiz Revolution Medicines Vollzeit

    Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target...